| Terminated | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First- NCT04497038 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Completed | Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma NCT04576572 | Inonu University | — |
| Completed | An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Adv NCT04022746 | M.D. Anderson Cancer Center | N/A |
| Completed | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer NCT03211416 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects NCT02409524 | Mirror Biologics, Inc. | Phase 2 |
| Completed | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar C NCT02234986 | CASI Pharmaceuticals, Inc. | Phase 2 |
| Completed | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma NCT02024087 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 1 / Phase 2 |
| Unknown | Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular NCT02418988 | Shenzhen SiBiono GeneTech Co.,Ltd | Phase 2 |
| Completed | Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer NCT01666756 | City of Hope Medical Center | Phase 1 |
| Completed | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder NCT02042443 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery NCT02072486 | Roswell Park Cancer Institute | N/A |
| Completed | Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be R NCT01900002 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery NCT01835223 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma NCT01839604 | AstraZeneca | Phase 1 |
| Completed | A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC NCT01829035 | National Cancer Center, Korea | Phase 3 |
| Completed | Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma NCT01777594 | GenSpera, Inc. | Phase 2 |
| Completed | Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma NCT01488487 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Terminated | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma NCT01405573 | National Cancer Institute, Naples | Phase 3 |
| Unknown | Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: M NCT01336452 | Yonsei University | N/A |
| Completed | MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery NCT01425879 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy NCT01239355 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery NCT01899261 | Albert Einstein College of Medicine | N/A |
| Completed | MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer NCT02578602 | University of Southern California | Phase 1 |
| Completed | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Met NCT01015833 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer NCT01008566 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361 | National Cancer Institute (NCI) | Phase 1 |